Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 6/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | LAP3 | P28838 | 3/20 | 0.44 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.43 |
| ▸ | NMT2 | O60551 | 1/20 | 0.42 |
| ▸ | NMT1 | P30419 | 1/20 | 0.42 |
| ▸ | GRN | P28799 | 1/20 | 0.42 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29645226 | 1.00 | MME (0.53) | MMEALDH1A1MEN1LMNAKMT2A | |
| SCHEMBL31289517 | 0.94 | MME (0.48) | MMEALDH1A1MEN1LMNAKMT2A | |
| SCHEMBL29816034 | 0.94 | MME (0.56) | MMEALDH1A1MEN1LMNAKMT2A | |
| SCHEMBL30586938 | 0.94 | MME (0.56) | MMEALDH1A1MEN1LMNAKMT2A | |
| SCHEMBL30586939 | 0.94 | MME (0.56) | MMEALDH1A1MEN1LMNAKMT2A | |
| SCHEMBL29624868 | 0.93 | MME (0.56) | MMEALDH1A1MEN1LMNAKMT2A | |
| SCHEMBL30974405 | 0.93 | MME (0.48) | MMEALDH1A1MEN1LMNAKMT2A | |
| SCHEMBL9576054 | 0.92 | ALDH1A1 (0.55) | MMEALDH1A1MEN1LMNAKMT2A | |
| SCHEMBL30381819 | 0.91 | FOLH1 (0.56) | MMEALDH1A1FOLH1NMT2NMT1 | |
| SCHEMBL29886740 | 0.91 | MME (0.45) | MMEALDH1A1MEN1LMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260091097-A1 | COMBINATION TREATMENT REGIMES FOR TREATING CANCER | BARINTHUS BIOTHERAPEUTICS NORTH AMERICA INC (US) | 2026-04-02 | — | — | US | disclosed |
| US-20260048133-A1 | METHODS AND COMPOSITIONS USING PEPTIDES AND PROTEINS WITH C-TERMINAL ELEMENTS | SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INST (US) | 2026-02-19 | — | — | US | disclosed |
| US-20250381281-A1 | METHODS OF MANUFACTURING PEPTIDE-BASED VACCINES | BARINTHUS BIOTHERAPEUTICS NORTH AMERICA INC (US) | 2025-12-18 | — | — | US | disclosed |
| US-20250339504-A1 | CANCER VACCINE WITH USE OF COMMON CANCER ANTIGEN COCKTAIL, TCR/CAR-T CELL THERAPEUTIC, COMPANION DIAGNOSTIC METHOD, AND METHOD FOR DIAGNOSING RISK OF CANCER ONSET BY DETECTING CIRCULATING TUMOR CELLS | NATIONAL CANCER CENTER (JP) | 2025-11-06 | — | — | US | disclosed |
| EP-4608437-A2 | COMBINATION TREATMENT REGIMES FOR TREATING CANCER | Barinthus Biotherapeutics North America, Inc. (US) | 2025-09-03 | — | — | EP | disclosed |
| EP-4608455-A1 | SELF-ASSEMBLING NANOPARTICLES | Barinthus Biotherapeutics North America, Inc. (US) | 2025-09-03 | — | — | EP | disclosed |
| US-20250242015-A1 | SELF-ASSEMBLING NANOPARTICLES | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2025-07-31 | — | — | US | disclosed |
| US-12370255-B2 | Peptide-based vaccines, methods of manufacturing, and uses thereof for inducing an immune response | BARINTHUS BIOTHERAPEUTICS NORTH AMERICA, INC. (US) | 2025-07-29 | — | — | US | disclosed |
| US-12290569-B2 | Methods and compositions using peptides and proteins with c-terminal elements | Sanford Burnham Prebys Medical Discovery Institute (US) | 2025-05-06 | — | — | US | disclosed |
| US-20250127887-A1 | Self-Assembling Nanoparticles Based On Amphiphilic Peptides | BARINTHUS BIOTHERAPEUTICS NORTH AMERICA, INC. (US) | 2025-04-24 | — | — | US | disclosed |
| CN-111602822-B | Liver fat synthesis inhibitor | 不二制油集团控股株式会社 | 2024-10-01 | — | — | CN | disclosed |
| US-20240269269-A1 | Self-Assembling Nanoparticles | VACCITECH NORTH AMERICA, INC. (US) | 2024-08-15 | — | — | US | disclosed |
| WO-2024097310-A2 | TARGETED NON-CHARGED-NUCLEIC ACID (NCNA) DELIVERY AND RELATED TUMOR PENETRATING NANOCOMPLEXES | IMPILO THERAPEUTICS, INC. (US) | 2024-05-10 | — | — | WO | disclosed |
| WO-2024092028-A2 | COMBINATION TREATMENT REGIMES FOR TREATING CANCER | VACCITECH NORTH AMERICA, INC. (US) | 2024-05-02 | — | — | WO | disclosed |
| WO-2024092030-A1 | SELF-ASSEMBLING NANOPARTICLES | VACCITECH NORTH AMERICA, INC. (US) | 2024-05-02 | — | — | WO | disclosed |
| EP-4294431-A1 | SELF-ASSEMBLING NANOPARTICLES BASED ON AMPHIPHILIC PEPTIDES | Vaccitech North America, Inc. (US) | 2023-12-27 | — | — | EP | disclosed |
| CN-117257980-A | Method, system and application for packaging and delivering exogenous protein by using heat-resistant nano caged protein particles | 东沃同泰(凤城)生物工程有限公司 | 2023-12-22 | — | — | CN | disclosed |
| US-11628202-B2 | Methods of reducing the need for surgery in patients suffering from benign prostatic hyperplasia | NYMOX CORPORATION (CA) | 2023-04-18 | — | — | US | disclosed |
| WO-2022177993-A1 | SELF-ASSEMBLING NANOPARTICLES BASED ON AMPHIPHILIC PEPTIDES | VACCITECH NORTH AMERICA, INC. (US) | 2022-08-25 | — | — | WO | disclosed |
| US-20220175941-A1 | METHODS AND COMPOSITIONS USING PEPTIDES AND PROTEINS WITH C-TERMINAL ELEMENTS | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE | 2022-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250127887-A1 | Self-Assembling Nanoparticles Based On Amphiphilic Peptides | IAPP, BRCA1, ANXA11 | MME 1318/4885ALDH1A1 4064/4885MEN1 449/4885 |
| US-20240269269-A1 | Self-Assembling Nanoparticles | UBE2B, CD4, UBE2G2 | MME 1690/4885ALDH1A1 1531/4885MEN1 1233/4885 |
| US-20260091097-A1 | COMBINATION TREATMENT REGIMES FOR TREATING CANCER | IL2, IFNG, ICOS | MME 4591/4885ALDH1A1 3087/4885MEN1 3778/4885 |
| US-20250242015-A1 | SELF-ASSEMBLING NANOPARTICLES | UBE2B, CD4, HRH1 | MME 1765/4885ALDH1A1 1530/4885MEN1 1283/4885 |
| US-20260048133-A1 | METHODS AND COMPOSITIONS USING PEPTIDES AND PROTEINS WITH C-TERMINAL ELEMENTS | CMKLR2, CRKL, CMKLR1 | MME 2437/4885ALDH1A1 4873/4885MEN1 2153/4885 |
| US-20250381281-A1 | METHODS OF MANUFACTURING PEPTIDE-BASED VACCINES | VIP, HM13, SPPL2B | MME 111/4885ALDH1A1 4817/4885MEN1 992/4885 |
| US-12370255-B2 | Peptide-based vaccines, methods of manufacturing, and uses thereof for inducing an immune response | MYD88, ICOS, CD4 | MME 987/4885ALDH1A1 4875/4885MEN1 3013/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.